Literature DB >> 8036790

Relative importance of immune and non-immune causes of platelet refractoriness.

H A Doughty1, M F Murphy, P Metcalfe, A Z Rohatiner, T A Lister, A H Waters.   

Abstract

In this prospective study, 26 consecutive patients being treated for haematological malignancies receiving standard (i.e. non-leucocyte-depleted) blood components were observed for the development of refractoriness to platelet transfusions. One hundred and sixteen of the 266 (44%) platelet transfusions failed to produce a satisfactory response. In 102/116 (88%), the poor response was in the presence of non-immune factors known to be associated with platelet refractoriness. Non-immune factors were present alone in 78/116 (67%), and in combination with immune factors in a further 24/116 (21%). Immune factors (HLA and platelet-specific antibodies) were present during 29/116 (25%) of unsuccessful platelet transfusions. Statistical analysis confirmed that platelet refractoriness was significantly associated with the presence of non-immune factors. The non-immune factors associated with refractoriness were often multiple, most frequently a combination of fever, infection and antibiotic therapy. This study provides evidence that immune mechanisms were not the predominant cause of platelet refractoriness in the patient population studied. It also suggests that measures for the prevention of HLA alloimmunisation, such as leucocyte depletion, may have a limited impact in reducing the incidence of refractoriness to platelet transfusions.

Entities:  

Mesh:

Year:  1994        PMID: 8036790     DOI: 10.1111/j.1423-0410.1994.tb00310.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  20 in total

1.  Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.

Authors:  Sherrill J Slichter; Douglas Bolgiano; Kuo-Jang Kao; Thomas S Kickler; Janice McFarland; Jeffrey McCullough; Robert Woodson
Journal:  Transfus Med Rev       Date:  2011-02-23

2.  Detection and Identification of Platelet-Associated Alloantibodies by a Solid-Phase Modified Antigen Capture Elisa (MACE) Technique and Its Correlation to Platelet Refractoriness in Multi platelet Concentrate Transfused Patients.

Authors:  R S Sarkar; J Philip; Neelesh Jain
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-29       Impact factor: 0.900

Review 3.  Platelet transfusion refractoriness: how do I diagnose and manage?

Authors:  Claudia S Cohn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Authors:  Sherrill J Slichter; Kathryn Davis; Helen Enright; Hayden Braine; Terry Gernsheimer; Kuo-Jang Kao; Thomas Kickler; Edward Lee; Janice McFarland; Jeffrey McCullough; Glenn Rodey; Charles A Schiffer; Robert Woodson
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

5.  Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.

Authors:  Nils Lachmann; Kremena Todorova; Harald Schulze; Constanze Schönemann
Journal:  Transfus Med Hemother       Date:  2013-05-08       Impact factor: 3.747

6.  How do I … implement diagnostic management teams in transfusion medicine?

Authors:  Jenna Wade; Christina L Dean; Scott M Krummey; John D Roback; Harold C Sullivan
Journal:  Transfusion       Date:  2019-12-10       Impact factor: 3.157

7.  Identification of platelet refractoriness in oncohematologic patients.

Authors:  Aline Aparecida Ferreira; Roberto Zulli; Sheila Soares; Vagner de Castro; Helio Moraes-Souza
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 8.  The HLA system: genetics, immunology, clinical testing, and clinical implications.

Authors:  Sung Yoon Choo
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

9.  Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding.

Authors:  Anthony D Sung; Richard C Yen; Yiqun Jiao; Alyssa Bernanke; Deborah A Lewis; Sara E Miller; Zhiguo Li; Joel R Ross; Alexandra Artica; Sadhna Piryani; Dunhua Zhou; Yang Liu; Tuan Vo-Dinh; Maureane Hoffman; Thomas L Ortel; Nelson J Chao; Benny J Chen
Journal:  Radiat Res       Date:  2020-08-01       Impact factor: 3.372

10.  A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.

Authors:  Phuong Vo; Enkhtsetseg Purev; Kamille A West; Emily McDuffee; Tatyana Worthy; Lisa Cook; Geri Hawks; Brian Wells; Reem Shalabi; Willy A Flegel; Sharon D Adams; Robert Reger; Georg Aue; Xin Tian; Richard Childs
Journal:  Br J Haematol       Date:  2020-02-21       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.